- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report
Over the next two decades, the cost of treating strokes in the United States is expected to more than double, topping more than $180 billion a year, according to new research.
Stroke
The main factor driving the increase: an aging population. The report, from the American Heart Association (AHA) and the American Stroke Association, was published May 22 in the journal .
"Strokes will absolutely strain the health care system," Dr. Bruce Ovbiagele, chairman of the department of neurology at the Medical University of South Carolina, said in an AHA news release.
One expert who reviewed the report agreed.
"The forecasts in this article are indeed dire -- the predicted direct and indirect costs of stroke could place a heavy burden on our society, and they may be underestimates," said Dr. Stanley Truhim, director of the Mount Sinai Stroke Center in New York City.
Read the full story here: http://bit.ly/18bDnhy
Source: Philly.com
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
